Over 490,000 spinal fusions are performed annually in the US of which 30% undergo revision due to failure to fuse. The mean age for spinal fusion increased from 48.8 to 54.2 years in 2008. In patients older than 50 years, the frequency of osteoporosis is reported to be 50% in women and 15% in man. These patients experience substantial deterioration in the quality of life, increased dependency on others, and reduced lifespan. Vertebral interbody spinal fusion through osteoinductive therapy was developed to prevent or reduce much of this suffering and extend lives. However, the current therapy for this, BMP-2 (Medtronic Infuseâ¢), has been shown to lead to significant inflammation, bone cyst formation, ectopic bone formation, nerve root injury, and cancer. Unlike BMP-2, Osteoactivin (rOA), a recombinant protein, induces bone fusion without inflammation or other complications. Preliminary data shows that it can successfully regenerate bone and it was successful in L4 and L5 spinal fusion in healthy male rats. Recently, a small peptide version of OA (OA-p) was discovered and shown to equivalently regenerate bone. This is exciting because a small peptide provides higher potency and targeting than a small molecule while maintaining a smaller size and decreases toxicity and accumulation potential than the whole protein, and so can be used repeatedly in the same individual. Therefore, in this Phase I SBIR study, we propose to evaluate the commercial feasibility of OA-p for spinal fusion, specifically by testing it in the ovariectomized osteoporotic rat. If successful, this work will demonstrate the potential of OA-p to be used as a novel osteoinductive therapy for accelerating spinal fusion without the complications associated with BMP-2, and with potential extension to other applications.
Public Health Relevance Statement: Public Health Relevance Osteoporosis is a major health care problem since approximately 10 million people over the age of 50 have been diagnosed with the disease and 33.6 million more are estimated to have low bone mass (osteopenia). Osteoactivin is a novel protein in bone and the proposed studies will generate new information regarding its effects and mechanisms of action on bone cell development and function. Once we understand its full effects on bone and how it works to promote bone formation, this information will be helpful in developing new therapeutic strategies to selectively enhance bone formation in patients with clinically significant bone loss.
Project Terms: Age; Animal Model; Animals; Autologous; Biological Markers; Biomechanics; Blood; bone; bone cell; Bone Cysts; bone loss; bone mass; bone morphogenetic protein 2; Bone Regeneration; Bone structure; Bone Transplantation; Businesses; Cephalic; Characteristics; Clinic; Clinical; clinically significant; Collaborations; commercialization; Data; Defect; Dependence; Deterioration; Development; Devices; Diagnosis; Disease; Doctor of Philosophy; dosage; Eligibility Determination; Evaluation; experience; Failure; Formulation; Frequencies; Gene Expression; Grant; Healthcare; Heterotopic Ossification; Histology; Hospitals; Human; in vivo; Individual; Inflammation; Inflammatory; Injury; Kidney; Lead; Longevity; Lung; male; Malignant Neoplasms; man; Medical; Miniature Swine; Modeling; Monitor; Mus; Musculoskeletal; Natural regeneration; Nerve; novel; novel therapeutic intervention; Ohio; older patient; operation; Operative Surgical Procedures; Orthopedics; osteoactivin; Osteogenesis; Osteopenia; Osteoporosis; Osteoporotic; Patients; Peptides; Phase; Physiological; Plant Roots; prevent; professor; Property; Proteins; Public Health; public health relevance; Quality of life; Randomized; Rattus; Recombinant Proteins; Recombinants; repaired; Reporting; Research; Risk; Route; Safety; Scientist; Sheep; Small Business Innovation Research Grant; small molecule; soft tissue; Spinal Fusion; spine bone structure; Spine surgery; stability testing; success; Surgeon; Testing; Therapeutic; Time; Toxic effect; Universities; Woman; Wor
